CN100408035C - 缬沙坦代谢物用于制备抑制血小板凝集药物的用途 - Google Patents

缬沙坦代谢物用于制备抑制血小板凝集药物的用途 Download PDF

Info

Publication number
CN100408035C
CN100408035C CNB03810864XA CN03810864A CN100408035C CN 100408035 C CN100408035 C CN 100408035C CN B03810864X A CNB03810864X A CN B03810864XA CN 03810864 A CN03810864 A CN 03810864A CN 100408035 C CN100408035 C CN 100408035C
Authority
CN
China
Prior art keywords
valsartan
platelet aggregation
methyl
metabolite
platelet
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB03810864XA
Other languages
English (en)
Chinese (zh)
Other versions
CN1652774A (zh
Inventor
A·马利宁
V·L·谢列布鲁安尼
R·L·韦布
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=29423705&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN100408035(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis AG filed Critical Novartis AG
Publication of CN1652774A publication Critical patent/CN1652774A/zh
Application granted granted Critical
Publication of CN100408035C publication Critical patent/CN100408035C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CNB03810864XA 2002-05-14 2003-05-13 缬沙坦代谢物用于制备抑制血小板凝集药物的用途 Expired - Fee Related CN100408035C (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US38037302P 2002-05-14 2002-05-14
US60/380,373 2002-05-14
US39501402P 2002-07-11 2002-07-11
US60/395,014 2002-07-11

Publications (2)

Publication Number Publication Date
CN1652774A CN1652774A (zh) 2005-08-10
CN100408035C true CN100408035C (zh) 2008-08-06

Family

ID=29423705

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB03810864XA Expired - Fee Related CN100408035C (zh) 2002-05-14 2003-05-13 缬沙坦代谢物用于制备抑制血小板凝集药物的用途

Country Status (22)

Country Link
US (2) US20050197372A1 (https=)
EP (1) EP1505965B1 (https=)
JP (1) JP4467427B2 (https=)
KR (1) KR101005367B1 (https=)
CN (1) CN100408035C (https=)
AT (1) ATE334677T1 (https=)
AU (1) AU2003267447B8 (https=)
BR (1) BR0310018A (https=)
CA (1) CA2482541A1 (https=)
CY (1) CY1105638T1 (https=)
DE (1) DE60307265T2 (https=)
DK (1) DK1505965T3 (https=)
ES (1) ES2268403T3 (https=)
IL (2) IL164774A0 (https=)
MX (1) MXPA04011282A (https=)
NO (1) NO20045245L (https=)
NZ (1) NZ536295A (https=)
PL (1) PL371728A1 (https=)
PT (1) PT1505965E (https=)
RU (1) RU2334512C2 (https=)
TW (1) TWI299663B (https=)
WO (1) WO2003094915A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110078640A (zh) * 2019-03-29 2019-08-02 浙江美诺华药物化学有限公司 一种缬沙坦中间体的合成方法

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040265238A1 (en) * 2003-06-27 2004-12-30 Imtiaz Chaudry Inhalable formulations for treating pulmonary hypertension and methods of using same
TW200523257A (en) * 2003-09-26 2005-07-16 Novartis Ag Use of organic compounds
AR057882A1 (es) 2005-11-09 2007-12-26 Novartis Ag Compuestos de accion doble de bloqueadores del receptor de angiotensina e inhibidores de endopeptidasa neutra
AR068814A1 (es) * 2007-08-29 2009-12-09 Orion Corp Composicion farmaceutica que comprende levosimendan y un inhibidor de la enzima conversina de la angiotensina (ace), y uso
RU2410104C1 (ru) * 2009-07-10 2011-01-27 Учреждение Российской академии медицинских наук Научный центр неврологии РАМН СПОСОБ СНИЖЕНИЯ АГРЕГАЦИОННОЙ АКТИВНОСТИ ТРОМБОЦИТОВ in vitro
US10478404B2 (en) 2014-01-24 2019-11-19 Arizona Board Of Regents On Behalf Of The University Of Arizona Materials, methods and devices for altering cell reactivity
CN111643557B (zh) * 2020-05-26 2022-02-22 四川省骨科医院 一种防治下肢深静脉血栓后遗症期的药物组合物及其制备方法和用途

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001082858A2 (de) * 2000-05-04 2001-11-08 Ipf Pharmaceuticals Gmbh Neue verbindungen zur behandlung inflammatorischer und kardiovaskulärer erkrankungen
WO2001097805A2 (en) * 2000-06-22 2001-12-27 Novartis Ag Solid valsartan pharmaceutical compositions
EP1197226A1 (en) * 1999-07-21 2002-04-17 Takeda Chemical Industries, Ltd. Preventives for the recurrence of cerebrovascular failure and agents for ameliorating troubles following cerebrovascular failure and inhibiting progress thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE312198T1 (de) * 1993-04-05 2005-12-15 Univ Utah Res Found Diagnose und behandlung von supravalvular aortic stenosis
US6395728B2 (en) * 1999-07-08 2002-05-28 Novartis Ag Method of treatment and pharmaceutical composition

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1197226A1 (en) * 1999-07-21 2002-04-17 Takeda Chemical Industries, Ltd. Preventives for the recurrence of cerebrovascular failure and agents for ameliorating troubles following cerebrovascular failure and inhibiting progress thereof
WO2001082858A2 (de) * 2000-05-04 2001-11-08 Ipf Pharmaceuticals Gmbh Neue verbindungen zur behandlung inflammatorischer und kardiovaskulärer erkrankungen
WO2001097805A2 (en) * 2000-06-22 2001-12-27 Novartis Ag Solid valsartan pharmaceutical compositions

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
"Pharmacokinetics, disposition and biotransformation of(14C)-radiolabelled valsartan in healthy male volunteers after asingle oral dose.". WALDMEIER F ET AL.XENOBIOTICA,Vol.27 No.1. 1997 *
Angiotensin II receptor antagonists. BURNIER M M ET AL.THE LANCET,Vol.355 No.9204. 2000 *
Antiplatelet action of losartan involves TXA2 receptorantagonism but not TXA2 synthase inhibition.. CHLOPICKI S ET AL.JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY,Vol.51 No.4-1. 2000 *
Comparative effects of angiotensin II AT-1-typereceptor antagonists in vitro on human platelet activation. MONTON MERCEDES ET AL.JOURNAL OF CARDIOVASCULAR PHARMACOLOGY,Vol.35 No.6. 2000 *
Effect of losartan on human platelet activation. JOSE I GUERRA CUESTA 等.JOURNAL OF HYPERTENSION,Vol.17 No.3. 1999 *
Studies on the antithrombotic action of AT1receptorantagonists. BUCZKO W ET AL.MEDICAL SCIENCE MONITOR,Vol.7 No.4. 2001 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110078640A (zh) * 2019-03-29 2019-08-02 浙江美诺华药物化学有限公司 一种缬沙坦中间体的合成方法
CN110078640B (zh) * 2019-03-29 2022-04-05 浙江美诺华药物化学有限公司 一种缬沙坦中间体的合成方法

Also Published As

Publication number Publication date
AU2003267447A1 (en) 2003-11-11
KR20050000532A (ko) 2005-01-05
JP4467427B2 (ja) 2010-05-26
ATE334677T1 (de) 2006-08-15
DE60307265T2 (de) 2007-07-19
CN1652774A (zh) 2005-08-10
HK1074395A1 (en) 2005-11-11
PL371728A1 (en) 2005-06-27
CY1105638T1 (el) 2010-12-22
TW200410686A (en) 2004-07-01
AU2003267447B8 (en) 2009-08-06
NZ536295A (en) 2006-12-22
US20100048654A1 (en) 2010-02-25
JP2005529913A (ja) 2005-10-06
PT1505965E (pt) 2006-11-30
MXPA04011282A (es) 2005-01-25
AU2003267447B2 (en) 2006-11-02
WO2003094915A1 (en) 2003-11-20
BR0310018A (pt) 2005-02-15
CA2482541A1 (en) 2003-11-20
KR101005367B1 (ko) 2010-12-30
IL164774A0 (en) 2005-12-18
DK1505965T3 (da) 2006-11-13
EP1505965A1 (en) 2005-02-16
RU2334512C2 (ru) 2008-09-27
RU2004136583A (ru) 2005-09-10
IL164774A (en) 2010-04-29
US20050197372A1 (en) 2005-09-08
ES2268403T3 (es) 2007-03-16
DE60307265D1 (de) 2006-09-14
TWI299663B (en) 2008-08-11
EP1505965B1 (en) 2006-08-02
NO20045245L (no) 2004-11-30

Similar Documents

Publication Publication Date Title
JP2020122015A (ja) 併用療法
US20100048654A1 (en) Use of valsartan or its metabolite to in hibit platelet aggregation
WO2009063215A2 (en) Use of crth2 antagonist compounds
EP3749326A1 (en) Certain (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides for treating anca associated vasculitides
EP2219645A2 (en) Use of crth2 antagonist compounds
US20110124683A1 (en) Use of CRTH2 Antagonist Compounds
US7109245B2 (en) Vasoconstrictor cannabinoid analogs
WO2013147161A1 (ja) ニペコチン酸誘導体及びその医薬用途
WO2013161980A1 (ja) シクロヘキサンジアミド誘導体及びその医薬用途
HK1074395B (en) Use of the metabolite of valsartan to inhibit platelet aggregation
WO2026058000A2 (en) Methods
CN121752271A (zh) 在疾病治疗中使用的稠合哌啶基二环化合物和相关化合物
CA2360127A1 (en) Method for treating chronic obstructive pulmonary disease
JP2003146907A (ja) アンジオテンシンｉｉ受容体拮抗剤を含有する医薬組成物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20080806

Termination date: 20120513